Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gujin Granule is a multi-component Traditional Chinese Medicine (TCM) formulation developed primarily for the treatment of non-small cell lung cancer (NSCLC). Developed by the Beijing Hospital of Traditional Chinese Medicine, it is a modern preparation of a classic formula designed to "strengthen the lungs" (Gold/Metal in TCM theory) and detoxify the body. The granule is typically used as an adjuvant therapy alongside platinum-based chemotherapy or targeted therapies. Its pharmacological profile is multi-targeted, involving the modulation of the immune microenvironment by enhancing CD4+ T-cell and Natural Killer (NK) cell activity, and the inhibition of tumor growth through the suppression of angiogenesis and induction of apoptosis. Clinical studies suggest that Gujin Granule can significantly reduce the side effects of chemotherapy, improve quality of life, and potentially extend progression-free survival in patients with advanced lung cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Gujin Granule.